|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's range||0.00 - 0.00|
|Beta (5Y monthly)||0.46|
|PE ratio (TTM)||29.79|
|Earnings date||03 May 2023 - 08 May 2023|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $308.47, marking a -1.88% move from the previous day.
Vertex Pharmaceuticals' (NASDAQ:VRTX) stock is up by 9.4% over the past three months. Since the market usually pay for...
BOSTON & ZUG, Switzerland, March 27, 2023--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and CRISPR Therapeutics (Nasdaq: CRSP) today announced that they have entered into a new non-exclusive licensing agreement for the use of CRISPR Therapeutics’ gene editing technology, known as CRISPR/Cas9, to accelerate the development of Vertex’s hypoimmune cell therapies for type 1 diabetes (T1D).